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Estimation of Hepatitis C Virus Infections Resulting
From Vertical Transmission in Egypt
Lenka Benova,1,2 Susanne F. Awad,1 F. DeWolfe Miller,3 and Laith J. Abu-Raddad1,4,5
Despite having the highest hepatitis C virus (HCV) prevalence in the world, the
ongoing level of HCV incidence in Egypt and its drivers are poorly understood.
Whereas HCV mother-to-child infection is a well-established transmission route, there
are no estimates of HCV infections resulting from vertical transmission for any country,
including Egypt. The aim of this study was to estimate the absolute number of new
HCV infections resulting from vertical transmission in Egypt. We developed a concep-
tual framework of HCV vertical transmission, expressed in terms of a mathematical
model and based on maternal HCV antibody and viremia. The mathematical model esti-
mated the number of HCV vertical infections nationally and for six subnational areas.
Applying two vertical transmission risk estimates to the 2008 Egyptian birth cohort, we
estimated that between 3,080 and 5,167 HCV infections resulted from vertical transmis-
sion among children born in 2008. HCV vertical transmission may account for half of
incident cases in the <5-year age group. Disproportionately higher proportions of verti-
cal infections were estimated in Lower Rural and Upper Rural subnational areas. This
geographical clustering was a result of higher-area-level HCV prevalence among women
and higher fertility rates. Conclusion: Vertical transmission is one of the primary HCV
infection routes among children <5 years in Egypt. The absolute number of vertical
transmissions and the young age at infection highlight a public health concern. These
findings also emphasize the need to quantify the relative contributions of other trans-
mission routes to HCV incidence in Egypt. (HEPATOLOGY 2015;61:834–842)
I
nfection with the hepatitis C virus (HCV) affects
2%-3% of the world’s population.1 Egypt has the
highest recorded prevalence of HCV in the world,
reaching 14.7% for HCV-antibody (Ab) positivity
among 15- to 59-year-olds in 2008.2 The viremic pop-
ulation of Egypt was estimated at over 6 million in
2008.3 This epidemic has been linked, in part, to a
mass campaign of parenteral antischistosomal therapy
in the 1950s-1980s, during which millions of people
received intravenous treatment in rural community
campaigns.4-6 The current pattern of HCV prevalence
is higher in rural areas, increases with age, and is
higher in men compared to women.2,7 Universal
screening of blood and blood products was introduced
in Egypt in June 1993.8 However, nosocomial and
other health care-related exposures remain associated
with HCV among adults and children.9-14 Parental,
and especially the mother’s, HCV serostatus, is an
additional risk factor for prevalent HCV infection
among children.11,15,16
Globally, vertical transmission appears to be the
most important route of HCV transmission among
children.17 However, the contribution of vertical trans-
mission to HCV incidence and its public health conse-
quences remain unknown. Maternal human
immunodeficiency virus (HIV) coinfection doubles the
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odds of HCV vertical transmission,18,19 but the moth-
er’s age, parity, HCV genotype, or breastfeeding do not
appear to be associated with the risk of vertical infec-
tion.20-26 There are no nationally representative esti-
mates of HCV prevalence among children under 15
years of age in Egypt. However, a systematic review of
HCV in Egypt identified six studies assessing HCV
prevalence among school children between 1992 and
2005 and found a range of HCV-Ab-positive prevalence
from 2.1% to 12.1%.13 In a cohort followed from birth
to 5 years of age in Lower Egypt, the estimated HCV
incidence was significantly higher during the first year
of life, compared to the 1- to 5-year age group (3.8 and
2.0 per 1,000 person-years, respectively).27
With over 80 million inhabitants, Egypt is the most
populous Arab country and continues to experience
high annual population growth (1.5%-1.9% in 2010-
2015).28 Despite a large reservoir of HCV infection in
the adult population as well as a relatively high fertility
rate, no published studies estimating the extent of ver-
tical transmission in Egypt were identified. Though
HCV prevalence among adults in Egypt is well charac-
terized, the level of ongoing HCV incidence and rela-
tive contribution of various transmission routes remain
uncertain and a subject of discussion.29-32
The first aim of this study was to develop a concep-
tual framework, expressed in terms of a mathematical
model, for estimating HCV vertical transmission in set-
tings of generalized HCV epidemics such as Egypt. The
second and main aim of this study was to estimate the
number of annual HCV infections resulting from verti-
cal transmission in Egypt and assess its contribution to
the overall HCV incidence in this country.
Materials and Methods
Conceptual Framework
We developed a framework to categorize children’s
vertical exposure to HCV according to maternal HCV
status (Fig. 1). Conceptually, only the presence of
maternal HCV viremia (RNA1) constitutes exposure to
vertical transmission. The existing estimates of HCV
viremia prevalence from Egypt relied on procedures
where HCV-RNA presence was only tested among indi-
viduals who first tested positive for HCV Abs (HCV1).
This procedure may have missed recently infected vire-
mic individuals without detectable HCV Abs and mis-
classified them as HCV RNA2. Therefore, we
conceptually specified four categories of maternal HCV
status and considered children born to HCV1/RNA1
and to HCV2/RNA1 women as vertically exposed.
Definition of Vertical Transmission
For the purpose of selecting vertical transmission
risk estimates based on primary studies to use in our
model, we defined vertically acquired HCV infection
as the presence of HCV Abs at or beyond 18 months
Fig. 1. Conceptual frame-
work diagram.
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of age and/or presence of HCV RNA on at least two
separate occasions by 18 months of age, among infants
vertically exposed to HCV.33 We also applied pub-
lished pooled estimates of the risk of vertical infection
among exposed children.
Model Description
National Estimates. We constructed a mathemati-
cal model estimating the total number of children ver-
tically infected with HCV in the 2008 annual birth
cohort in Egypt. The population used in the model
was stratified into groups according to maternal HCV
status (HCV1/RNA1 and HCV2/RNA1) and mater-
nal age group. The number of vertically infected chil-
dren was modeled as a function of the number of
women in reproductive age (by HCV status and age
group), their age-specific fertility rates, risk of HCV
vertical transmission, and risk of dying between birth
and 18 months of age (Equation (1), Fig. 2). I c is the
absolute number of children born in 2008 who are
alive and vertically infected with HCV at age 18
months. qmHCV1=RNA1!c and qmHCV-=RNA1!care the risks
of vertical transmission to children born to HCV1/
RNA1 women and HCV2/RNA1 women, respec-
tively. The index i labels the i-age group (5-year age
intervals) in the female population of reproductive age
(15-49 years old). BðiÞ is the total number of births to
women in each age group, based on the number of
women in each age group and the age-specific fertility
rate in the age group. ImHCV1ðiÞis the prevalence of
HCV1 among currently married women in each age
group. p
m
HCV1=
RNA1 ðiÞ is the proportion of HCV1 cur-
rently married women in each age group that is
RNA1. f
m
HCV -=
RNA1 is the fraction of mothers that are
HCV2, but RNA1, as a proportion of the size of the
HCV1/RNA1 group of women. We structured our
model in terms of this fraction to utilize the best
available direct empirical data to capture this contribu-
tion.34 l is the risk of dying between birth and 18
months of age. XHCV1=RNA1ðiÞ and XHCV -=RNA1ðiÞ
are the number of children born to HCV1/RNA1
and HCV2/RNA1 mothers, respectively.
Subnational Estimates. To evaluate the geo-
graphical distribution of the total number of chil-
dren vertically infected with HCV in Egypt, we
calculated the number of children vertically infected
with HCV for each of the six subnational areas in
Egypt, by maternal HCV status and age group
(Equation (2), Fig. 2). Here, I careais the absolute
number of children born in 2008 who are alive and
vertically infected with HCV at age 18 months in an
area, where (Equation (3), Fig. 2).
Parameterization
Demographic Estimates. The data sets available
from the most recent Egypt Demographic and Health
Survey (EDHS) in 2008 were used to calculate nation-
ally and subnationally representative HCV biomarkers
in the 15-59 age bracket. The 2008 EDHS report pro-
vided nationally and subnationally representative esti-
mates of fertility.2 The model of vertical transmission
was based on the 2008 annual cohort of live births in
Egypt (Table 1). The population of women ages 15-49
(in 5-year age groups) in 2008 was obtained from the
United Nations population projections (medium vari-
ant projection),28 and their distribution into the six
subnational areas was based on the distribution of the
total population in the most recent population census
preceding the 2008 EDHS survey, conducted in
2006.35 The six subnational areas are Urban governo-
rates (Cairo, Alexandria, Suez, and Port Said), Lower
Urban Egypt, Lower Rural Egypt, Upper Urban
Egypt, Upper Rural Egypt, and Frontier governorates,
as defined in the 2008 EDHS survey sampling
strategy.2
Fig. 2. Equations (1), (2), and (3).
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The 2008 EDHS was the source for the estimates of
national and subnational age-specific fertility rates
(ASFRs; number of live births per 1,000 women per
year) in 5-year age groups (Table 2). We assumed non-
differential fertility and pregnancy outcomes by HCV
status.36 The risk of dying between birth and 18
months of age was calculated for Egypt overall and for
each subnational area by taking the infant mortality rate
(risk of dying in the first year of life, per 1,000 births)
and adding the equivalent of 6 months of the child
mortality rate (risk of dying between first and fifth
birthdays, per 1,000 births), as provided by the 2008
EDHS for the 10-year period preceding the survey.2
The resulting risk of dying between birth and 18
months of age, expressed as a proportion of births,
ranged from a low of 1.53% in Lower Urban areas to a
high of 3.95% in Upper Rural areas, with a national
level of 2.92%. Owing to the mild progression of verti-
cally acquired HCV among children, the risks of dying
before 18 months of age were assumed not to differ
between HCV-infected and uninfected children.37
Epidemiological Estimates. National prevalence of
HCV-Ab positivity and the proportion of HCV-Ab-
positive women with active HCV viremia were
calculated for currently married women in 5-year age
groups using EDHS 2008 data sets provided by MEA-
SURE DHS (Demographic and Health Surveys), adjust-
ing for complex survey design with the svyset command
in Stata/SE software (version 12; StataCorp LP, College
Station, TX). As shown in the conceptual framework, a
proportion of HCV-Ab negative women may be
RNA1, reflecting early acute HCV infection.38 The
2008 EDHS evaluated HCV viremia only among those
who were HCV-Ab positive and would therefore not
have identified such cases. Based on a study from Egypt,
we estimated that the number of HCV2/RNA1 moth-
ers was 3% of the number of HCV1/RNA1 mothers.34
The prevalence of HCV1 and RNA1 was estimated
among currently married women in each subnational
area, but because of limited sample size could not be
estimated further within each age group. Therefore,
the age-group estimates of HCV1 prevalence and the
proportion RNA1 among HCV1 within the six sub-
national areas were calculated by scaling the national
estimates in each age group by a factor obtained by
dividing the overall subnational area prevalence by the
overall national prevalence. No separate estimates of
vertical transmission by mother’s HIV serostatus were
produced given that the prevalence of HIV in Egypt is
<1%.39-41
Risk of Vertical Transmission. Two groups of ver-
tically exposed children were identified in the concep-
tual framework according to maternal HCV status:
HCV1/RNA1 and HCV2/RNA1. However, no risk
estimates of vertical transmission from HCV2/RNA1
mothers were identified in the existing literature.
Therefore, estimates capturing the risk of vertical
transmission from HCV1/RNA1 were applied to
births occurring to all viremic women, irrespective of
HCV-Ab status. Two estimates of the risk were used
separately in the mathematical model in order to
obtain a credible range. Risk estimate A was based on
a cohort study in Egypt, which estimated the vertical
transmission risk at 3.5% (95% confidence interval
Table 2. National and Subnational Age-Specific Fertility Rates (Number of Live Births Per 1,000 Women Per Year)
in 5-Year Age Groups Among Currently Married Women in Egypt
Subnational Area Lower Urban Lower Rural Upper Urban Upper Rural Urban Govs Frontier Govs Egypt Overall
Age group, years 15-19 25 60 41 68 24 55 50
20-24 142 191 130 204 127 160 169
25-29 173 188 191 201 166 201 185
30-34 114 101 154 140 119 147 122
35-39 58 46 65 74 61 73 59
40-44 5 10 10 32 23 23 17
45-49 0 0 4 6 2 6 2
Source: EDHS 2008 report.
Abbreviation: Govs, governorates.
Table 1. Fertility and Number of Live Births to Currently
Married Women in Egypt in 2008, by Age Group
Age Group
Female Population
(2008)* ASFR†
Number of Births
(2008)‡
15-19 3,934,839 50 196,742
20-24 3,967,574 169 670,520
25-29 3,422,792 185 633,217
30-34 2,695,181 122 328,812
35-39 2,270,714 59 133,972
40-44 2,132,325 17 36,250
45-49 1,959,858 2 3,920
Total 20,383,283 2,003,432
Sources of data:
*World Population Prospects: The 2010 Revision.
†Source: EDHS 2008 report (estimates of ASFR for the 36-month period pre-
ceding the survey).
‡Expected number of births, calculated by authors.
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[CI]: 1.5-6.7).42 Risk estimate B was from the most
recent global systematic review and meta-analysis,
which estimated the pooled risk of vertical transmis-
sion to children born to HIV-negative, HCV1/RNA1
mothers at 5.8% (95%CI: 4.2-7.8).43
Uncertainty Analyses
Uncertainty analyses were conducted for the
national and subnational estimates of the number of
children vertically infected by HCV. For this purpose,
20,000 runs of the model were implemented using
Monte Carlo sampling from binomial probability dis-
tributions incorporating the sample sizes of the source
studies for the following parameters: prevalence of
HCV1 among currently married women by age group
(ImHCV1ðiÞ); the proportions of HCV1 currently mar-
ried women in each age group that are RNA1
(p
mHCV1=
RNA1 ðiÞ); and the two vertical transmission risk
estimates (risk estimate A and risk estimate B). This
set of new parameters was then used to calculate two
estimates of the number of children infected, for risk
estimate A and risk estimate B. Distributions for the
estimated number of children infected were then gen-
erated and used to calculate the mean and associated
95% CI.
Contribution of Vertical Transmission to
Incidence
Current HCV incidence in Egypt remains uncertain.
Overall annual HCV incidence rate in published cohort
studies in Egypt ranges between 0.8 and 6.8 per 1,000
person-years.13 Based on analyses of these incidence
studies and HCV prevalence age distribution, it is pre-
dicted that the annual national incidence is likely to
exceed 100,000 cases.29-31 In order to quantify the con-
tribution of vertical transmission to the estimated num-
ber of annual incident HCV infections among children,
we used two published estimates of HCV incidence.
First, we used a nationally representative estimate of the
average annual HCV incidence rate experienced by the
living Egyptian cohort in the 0-5-year age group.30 Sec-
ond, we drew on a cohort study from Lower Egypt, a
region with higher than national prevalence of HCV,
which estimated HCV incidence in the first year of life
at 3.8 per 1,000 person-years.27
Results
We estimated that the national prevalence of HCV1
among 15- to 49-year-old currently married women
was 11.7% (95% CI: 10.6-12.9). In this group,
59.9% were estimated to be viremic, resulting in HCV
viremia prevalence of 7.0% (95% CI: 6.2-8.0). The
prevalence of HCV-Ab positivity on the national level
increased with women’s age, ranging from approxi-
mately 5% among women of ages 15-29 to 24.1% in
the age group 45-49 (Fig. 3). The highest prevalence
of HCV-Ab positivity among currently married
women was recorded in Lower Rural Egypt (14.9%)
and lowest in Frontier governorates (2.4%). The pro-
portion of HCV-Ab positive women who were viremic
ranged from 54.5% in Urban governorates to 70.3%
in Upper Urban Egypt (Table 3).
We estimated that in 2008, 20.3 million women
aged 15-49 in Egypt gave birth to 2 million children.
The estimated number of vertical HCV infections in
this birth cohort reached 3,080 (95% CI: 1,146-
5,465) based on risk estimate A and 5,167 (95% CI:
Fig. 3. Fertility rates and
HCV biomarkers among cur-
rently married women in
Egypt, by age group.
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3,954-6,544) based on risk estimate B (Fig. 4). The
two subnational areas where the proportion of overall
vertical infections was greater than the proportion of
total births were Lower Rural (31.7% of births and
36.5% of vertical infections) and Upper Rural (26.6%
of births and 34.4% of vertical infections), as shown
in Fig. 5. The lowest proportion of all vertical infec-
tions was estimated to occur in Frontier governorates
(0.9%).
Based on estimates of HCV incidence in Egypt of
at least 100,000 new infections per year, vertical trans-
mission accounts for 5% of the total HCV incidence
in Egypt at most. However, based on the estimate of
10,000 annual incident cases in the 0-5-year age
group, vertical transmission could account for between
31% and 52% of annual HCV infections in this age
group. The estimate of HCV incidence in children <1
year from the cohort in Lower Egypt would result in
7,600 HCV infections in the 2008 birth cohort. Verti-
cal transmission could thus account for 41%-68% of
annual incident cases among children <1 year.
Discussion
We modeled the number of HCV vertical infections
based on demographic characteristics of the Egyptian
population, epidemiological estimates of HCV preva-
lence among currently married women in reproductive
age, and two separate robust estimates of the risk of
HCV vertical transmission. The resulting estimates
showed that between 3,000 and 5,000 children in the
2008 birth cohort were vertically infected with HCV.
Lower Rural and Upper Rural subnational areas
together contributed more than 7 in every 10 incident
infections occurring through this mode of transmission
in Egypt. This geographical clustering of HCV vertical
infections was largely driven by the combination of
higher HCV prevalence and higher fertility rates in
these subnational areas.
The HCV epidemic in Egypt is of similar scale to
the HIV epidemic in sub-Saharan Africa. In this con-
text, all potential transmission routes need to be exam-
ined with the view of being addressed by public health
interventions. The national estimate of HCV incidence
Table 3. Calculation of HCV1 Prevalence and Proportion of HCV1 That Are RNA1 Among
Currently Married Women, by Age Group and Subnational Area
Subnational
Area Indicator Estimate (%) 95% CI
% RNA1
(of HCV1)
Factor
(Regional/ National)
Age Group (Years)
15-19
(%)
20-24
(%)
25-29
(%)
30-34
(%)
35-39
(%)
40-44
(%)
45-49
(%)
Lower Urban % HCV1 8.2 5.7-11.7 57.3 0.70 3.6 3.8 3.6 7.7 9.1 14.9 16.9
% RNA1 4.7 3.0-7.2 0.96 72.5 51.1 59.9 54.8 58.2 55.2 58.3
Lower Rural % HCV1 14.9 12.8-17.3 58.3 1.27 6.6 6.9 6.5 14.0 16.6 27.0 30.7
% RNA1 8.7 7.1-10.6 0.97 73.6 52.0 60.8 55.7 59.1 56.1 59.3
Upper Urban % HCV1 6.9 4.4-10.7 70.3 0.59 3.1 3.2 3.0 6.5 7.7 12.5 14.2
% RNA1 4.9 3.0-7.7 1.17 88.9 62.7 73.4 67.2 71.3 67.7 71.5
Upper Rural % HCV1 13.9 11.8-16.3 65.8 1.19 6.2 6.4 6.1 13.1 15.4 25.2 28.6
% RNA1 9.1 7.4-11.2 1.10 83.1 58.7 68.7 62.9 66.7 63.3 66.9
Urban Govs % HCV1 7.1 4.8-10.3 54.5 0.61 3.2 3.3 3.1 6.7 7.9 12.9 14.6
% RNA1 3.9 2.4-6.3 0.91 68.9 48.6 56.9 52.1 55.3 52.5 55.5
Frontier Govs % HCV1 2.4 1.1-5.4 65.8 0.21 1.1 1.1 1.0 2.3 2.7 4.3 4.9
% RNA1 1.6 0.6-4.1 1.10 83.2 58.7 68.7 63.0 66.8 63.4 67.0
Egypt national % HCV1 11.7 10.6-12.9 59.9 5.2 5.4 5.1 11.0 13.0 21.2 24.1
% RNA1 7.0 6.2-8.0 75.7 53.4 62.5 57.3 60.8 57.7 61.0
% HCV1 refers to proportion of all women with HCV Abs (HCV1). % RNA1 refers to proportion of all women with active infection (RNA1). % RNA1 (of HCV1)
refers to proportion of HCV1 women with active infection (RNA1). Source of estimates: EDHS 2008 data sets. Age group estimates within subnational areas were
calculated by multiplying national estimates for each age group by the area factor.
Abbreviation: Govs, governorates.
Fig. 4. Estimates of the number of children from the 2008 annual
birth cohort vertically infected by HCV and alive at age 18 months
(interquartile range and 95% CI).
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in Egypt remains contentious, and the relative contri-
butions of the transmission routes that drive this inci-
dence are not well established. To our knowledge, this
is the first published study to estimate the contribution
of a specific HCV transmission route to HCV inci-
dence in Egypt. Moreover, this research is also the first
to estimate, for any country, the number of HCV
infections resulting from vertical transmission. Our
estimates of the absolute and relative contribution of
vertical transmission to HCV incidence are essential
for planning health service provision and development
of appropriate interventions. Indirectly, but impor-
tantly, our findings show that transmission routes other
than mother-to-child transmission contribute the bulk
(>90%) of the overall HCV incidence in Egypt. The
relative contribution of each of these remaining routes
is yet to be quantified.
Our model relied on robust demographic estimates
of the number of women in reproductive age and their
fertility rates based on a nationally representative sur-
vey of birth history in the 36 months preceding data
collection in 2008. HCV prevalence was obtained
from the 2008 EDHS, which used third-generation
HCV-Ab assay and confirmed all positive and retested
5% of negative samples. The quantitative RNA poly-
merase chain reaction test used in this survey would
have been able to detect viral load at a lower limit of
50 IU/mL. We assumed that children in the 2008
annual cohort were born to currently married women
and calculated the HCV biomarker prevalence among
women by age group accordingly. However, among
currently married women selected for HCV testing,
7.3% had missing data for HCV biomarkers, mainly
because of refusal to provide blood or absence at the
time of blood sample collection.
The 2008 EDHS tested for HCV viremia only in
the HCV-Ab-positive samples. Therefore, infections
occurring several weeks before this serosurvey may
have tested as HCV-Ab negative and been classified as
HCV2/RNA2 despite being viremic. We adjusted for
this potential misclassification using the best available
estimates from Egypt. To capture the potential varia-
tion in the estimates of vertical transmission risk, this
study relied on two separate estimates, one based on
data from Egypt and the other a result of a recent
meta-analysis of high-quality global studies.42,43 Both
sources also provided estimates of vertical transmission
risk to children born to HCV1/RNA2 mothers and
showed that the vertical transmission risk was 0%, in
line with our conceptual framework. We defined verti-
cally acquired HCV infection as the persistence of
HCV Abs and/or continued presence of HCV RNA
on at least two separate occasions by 18 months of
age. Further spontaneous clearance may occur after
this age, and our estimate of vertical infections could
be higher than the eventual number of chronic HCV
infections in the birth cohort.44 Our assessment of the
contribution of HCV vertical transmission to HCV
incidence among the <5- and <1-year-old children
was based on the two best sources of incidence esti-
mates available for Egypt. However, given that both
studies may have overestimated current HCV inci-
dence for these age groups, the contribution of HCV
vertical transmission to the total HCV incidence in
the 0-5-year and <1-age groups, based on our results,
may be underestimated.
Several potential steps to reducing the number of vertical
HCV infections may exist. The current HCV treatment
regimen of pegylated interferon and ribavirin is contraindi-
cated during pregnancy,38 and new drugs have not yet been
Fig. 5. Comparison of the
proportions of total popula-
tion, total births, and total
number of vertical infections
by subnational area.
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evaluated for use in pregnant women.45,46 One potential
intervention could offer HCV treatment to women before
conception.47 Whereas currently only 2% of women in
Egypt report ever having been tested for HCV,2 testing
could be made available during premarital counseling
and lead to treatment referral.48 Children born to
HCV-infected pregnant women could be clinically fol-
lowed and treated at earlier stages of the disease. Whereas
HCV treatment is currently not offered to children <2
years of age, 55%-93% of children in the 2-17 age group
undergoing combination treatment achieve sustained viral
response.49
In conclusion, we developed a conceptual framework of
HCV vertical transmission, expressed in terms of a mathe-
matical model, to estimate the number of HCV infections
resulting from mother-to-child transmission in the 2008
birth cohort in Egypt. We estimated that between 3,000
and 5,000 children from this birth cohort were vertically
infected by HCV. This represents approximately 5% of all
incident HCV cases in Egypt, but may account for
between one and two thirds of incident HCV in the 0-5-
year age group. The absolute number of vertical transmis-
sions is of public health importance, as is the young age at
infection and resulting potential lifelong HCV infection
and its clinical and social consequences. In light of the sig-
nificance of vertical transmission as an HCV infection
route among children in Egypt, we encourage further
research to better understand this transmission route and
assess potential interventions to prevent infection. Such
research should be conducted in conjunction with studies
estimating the relative contributions of other transmission
routes to the overall HCV incidence in Egypt.
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